<DOC>
	<DOCNO>NCT02633384</DOCNO>
	<brief_summary>Parenteral nutrition associate cholestasis ( PNAC ) common complication prolong exclusive parenteral nutrition ( PN ) . Infants subject major surgery often unable receive enteral nutrition long period time , require exclusive PN . In preterm infant , hepatic immaturity predispose factor . Intravenous lipid emulsion ( ILE ) use PN may promote PNAC protect depend composition . Medium chain triglyceride ( MCT ) may hepatic protective effect . Long chain triglyceride ( LCT ) n-3 family may protect PNAC . In several new-generation emulsion , α-tocopherol content high gamma-tocopherol content , act antioxidant , prevent lipid peroxidation . The incidence severity PNAC term near-term infant subject corrective surgery congenital abnormality need prolonged PN use ILE SMOFlipid® Lipofundin® compare . The investigator hypothesise SMOFlipid® protective PNAC Lipofundin® . Single-center , randomize , control double-blinded trial consecutive neonate admit NICU , gestational age 34 week , undergo corrective surgery congenital anomaly digestive tract indirectly affect digestive tract . Recruitment PN ILE start within first 48 hour birth . Minimum intervention : exclusive PN least 1 week . Main outcome : incidence cholestasis ( conjugate serum bilirubin &gt; 1 mg/dl [ 34 mmol/L ] ) . Severity cholestasis evaluate magnitude serum conjugate bilirubin serum γ-glutamyltranspeptidase ( GGT ) . Mixed effect regression model use take account correlation structure measure time . Crude adjust odds-ratios correspond 95 % confidence interval calculate .</brief_summary>
	<brief_title>Reduction Neonatal Parenteral Nutrition Associated Cholestasis Through Lipid Emulsions</brief_title>
	<detailed_description>BACKGROUND . Parenteral nutrition associate cholestasis ( PNAC ) common complication prolong exclusive parenteral nutrition ( PN ) . PNAC neonates infant multifactorial , include underlie pathology effect certain PN nutrient . In preterm infant , hepatic immaturity , predispose factor . Infants subject major surgery often unable receive enteral nutrition long period time , require exclusive PN . After , enteral nutrition slowly introduce alongside reduction PN . In major surgery congenital malformation digestive tract , additional risk factor PNAC absence enteral nutrition , intestinal bacterial translocation sepsis . Jejunal atresia gastroschisis independent risk factor PNAC . In short bowel syndrome , change bile acid enterohepatic cycle may also contribute PNAC . Intravenous lipid emulsion ( ILE ) use PN may promote PNAC protect depend composition . Phytosterols contain ILE implicate PNAC newborn disrupt bile-acid homeostasis . High intake soy-based fatty acid ( FA ) n-6 ILE , especially palmitate , may contribute PNAC since precursor arachidonic acid , pro-inflammatory mediator . Medium chain triglyceride ( MCT ) may hepatic protective effect . Hence , ILE contain relatively high amount MCT , Lipofundin® ( B. Braun ) theoretically might advantageous protect PNAC . Long chain triglyceride ( LCT ) n-3 family may protect PNAC thorough anti-inflammatory activity . The Omegaven® ( Fresenius Kabi ) , exclusively base LCT n-3 prove prevent reverse PNAC neonates . In several new-generation emulsion , include SMOFlipid® ( Fresenius Kabi ) , report α-tocopherol content 4- 5-fold high alpha-tocopherol content soy-oil emulsion . The α-tocopherol isoform act antioxidant , prevent lipid peroxidation attributable high content long-chain polyunsaturated fatty acid ( LC-PUFA ) . The ILE Lipofundin® ( B Braun ) , compose 50 % LCT ( soybean oil ) 50 % MCT ( coconut oil ) . The new generation ILE SMOFlipid® ( Fresenius Kabi ) compose 30 % LCT n-6 ( soybean oil ) , 30 % MCT ( coconut oil ) , 25 % monounsaturated fatty acid ( olive oil ) , 15 % LCT n-3 ( fish oil ) α-tocopherol . A systematic review find low bilirubin level child intestinal failure condition receive parenteral n-3 ILE compare n-6 ILE . However , conclude current data insufficient support use parenteral n-3 ILE child , suggest trial examine long-term clinical outcome harm . Among several study compare effect different ILEs PNAC child , retrospective study Pischler et al . ( 2014 ) compare SMOFlipid® Lipofundin® . This study include 127 child age 0-16 year , include 34 premature infant 59 child surgical condition , include necrotizing enterocolitis . Until 2011 Lipofundin® use PN medical-surgical neonatal intensive care unit ( NICU ) Hospital Dona Estefânia . The availability SMOFlipid® lead investigator compare effect ILE liver test associate PNAC neonate subject corrective surgery major congenital abnormality , since best knowledge prospective study make comparison specifically population . OBJECTIVE . To compare incidence severity PNAC term near-term infant subject corrective surgery congenital abnormality need prolonged PN use ILE SMOFlipid® Lipofundin® . The investigator hypothesise use SMOFlipid® may protective PNAC Lipofundin . METHODS . Design : single-center , randomize , control double-blinded trial : prescribing physician unaware type ILE administer pharmacist prepared randomized individual intervention aware liver status participant . Simple randomization perform pharmacist ( MLR ) use computer generate random number table . Were consider eligible every consecutive neonate admit NICU , gestational age 34 week , require corrective surgery congenital anomaly digestive tract indirectly affect digestive tract ( eg , diaphragmatic hernia ) . Recruitment occur first 48 hour birth , PN ILE initiate within first 48 hour birth . Main variable record : - Weekly measurement serum : total bilirubin , conjugate bilirubin , GGT , alanine -aminotransferase ( ALT ) aspartate aminotransferase ( AST ) , alkaline phosphatase triglyceride . - Daily parenteral lipid intake ( g/Kg ) - Reasons reduce stop ILE Secondary variable record : - Gestational age , birth weight , prenatal diagnosis congenital abnormality - Main secondary diagnosis - Major surgery ( date/ day life ) - Events , especially infectious event ( date/ day life ) - Enteral feeding initiation ( date/ day life ) - Enteral feeding : type feed mode administration . The percent enteral intake relation daily fluid intake record ( date/ day life ) : 0-50 % full enteral feeding . - Daily weight ( g ) - Weekly length ( cm ) head circumference ( cm ) - Weekly every 2 week measurement serum : total blood count , ionogram , calcium , phosphorus magnesium Potential confounders affect liver function : - Sepsis accord describe criterion - Phenobarbital treatment abstinence syndrome secondary sedative analgesic drug use postsurgical period - Use ursodeoxycholic acid Parenteral nutrition protocol base National Consensus Neonatal PN . Whenever possible PN ILE initiate within first 24 hour birth . As Pharmacy Service Hospital available prepare individualized PN weekend , infant admit period initiate standard solution contain glucose , calcium aminoacids . Thereafter , patient receive similar aminoacid , glucose , electrolyte vitamin PN solution plus ILE ( SMOFlipid® Lipofundin® ) . ILE reduce 0.5-1.5g/kg/d : Hypertriglyceridemia ( &gt; 250 mg / dL ) Hyperglycemia ( &gt; 150 mg / dL ) Unconjugated bilirubin &gt; 12 mg/dL Acute phase sepsis Pulmonary hypertension If cholestasis appear , ILE restrict 2-2.5 g/kg/d , amino acid restrict 2-2.5 g/kg/d glucose limit 12 mg/kg/minute Enteral nutrition protocol group . Minimal enteral feeding initiate bowel sound audible , significant abdominal distention bilious bloody gastric residual absent . Initially , feed administer continuously , change bolus feed soon infant tolerate . Mother 's milk prefer . However , depend patient 's condition semi-elemental ( Pepti-Junior® , Danone ) elemental formula ( Neocate® , Nutricia ) may prefer . Later , formulas replace mother 's milk soon tolerate , mother 's milk insufficient unavailable , preterm formula ( Miltina Prem® , Humana GmbH , Germany ) may use preterms infant formula ( Nan 1® , Nestlé ) full-term infant . Data collection storage : Excel® calculation table ( Microsoft Office 2007® ) . Statistical analysis support Research Unit Centro Hospitalar de Lisboa Central . Categorical data present frequency ( percentage ) , continuous variable mean standard deviation ( SD ) median inter-quartile range ( 25th percentile-75th percentile ) , appropriate . Mixed effect regression model use take account correlation structure measure time . Crude adjust odds-ratios correspond 95 % confidence interval calculate . The level significance α = 0.05 . Data analysis perform use software SPSS 22.0 ( SPSS Windows , Rel . 22.0.1 . 2013 . SPSS Inc. , Chicago , Il , EUA ) Stata ( StataCorp . 2013 . Stata Statistical Software : Release 13 . College Station , TX : StataCorp LP. ) . Measures outcome : Cholestasis cholestasis severity incidence rate associate 95 % confidence interval access intervention group . Cholestasis severe cholestasis incidence rate compare calculate relative risk Number Needed Harm ( NNH ) association 95 % confidence interval . Relative efficacy measure ( hazard ratio ) possibly odds ratio use group homogeneity find . Identification confounders use multivariate analysis logistic regression .</detailed_description>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Fat Emulsions , Intravenous</mesh_term>
	<mesh_term>Sorbitol</mesh_term>
	<criteria>neonate admit NICU , gestational age 34 week , undergo corrective surgery congenital anomaly digestive tract indirectly affect digestive tract ( eg , diaphragmatic hernia ) initiation PN ILE within first 48 hour birth . prenatal early neonatal ( within first 72 hour birth ) diagnose congenital acquire hepatobiliary disease , biliary atresia , choledochal cyst , inborn error metabolism , intrahepatic familial cholestasis , infectious hepatitis , neonatal idiopathic hepatitis , biliary lithiasis abnormality liver function test . later neonatal diagnosis mention pathology . congenital condition affect liver function , meconium ileus associate cystic fibrosis . treatment ursodeoxycholic acid , interruption PN 48 hour reason , except postsurgical period corrective surgery main condition , transference another unit complete 7 day PN .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>48 Hours</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Parenteral nutrition associate cholestasis</keyword>
	<keyword>Intravenous lipid emulsion</keyword>
	<keyword>Surgical neonate</keyword>
	<keyword>Congenital gastrointestinal abnormality</keyword>
</DOC>